Cryo-Cell International, Inc. (CCEL)

Over the past six months, Cryo-Cell International's market capitalization has experienced a decreasing trend. As of February 4, 2026, its market cap was $26.91M, representing a -1.46% decrease over the past 30 days and a -2.9% decrease over the last 12 months. In October 2025, Maxim Group downgraded Cryo-Cell International (CCEL) to a "Hold" rating. Currently, the consensus among Wall Street analysts, based on one analyst's rating in the last 12 months, is to "Hold" CCEL shares. The stock's 52-week range has been between a low of $3.10 and a high of $8.79.

No specific information regarding demand seasonality for Cryo-Cell International, Inc.'s products and services was found in the provided search results.

Cryo-Cell International, Inc. specializes in cellular processing and cryogenic storage, focusing on the collection and preservation of umbilical cord blood and tissue stem cells. The company operates in the Healthcare sector, specifically in the Medical Care Facilities and Healthcare Providers & Services industry. Its major products and services include the cryopreservation of umbilical cord blood and cord tissue stem cells for family use, as well as the manufacturing of PrepaCyte CB units. Cryo-Cell also engages in public cord blood banking.

Cryo-Cell International, headquartered in Oldsmar, Florida, has a broad international reach, serving over 500,000 families across 87 countries. Its operations extend to numerous countries including Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, India, Mexico, Nicaragua, Pakistan, Panama, Peru, Republica Dominicana, the United States, and Venezuela.

Cryo-Cell International is recognized as a pioneer and an internationally recognized leader in the cord blood banking industry, maintaining a strong reputation. The COVID-19 pandemic reportedly led to increased interest in the company's services, highlighting the importance of regenerative medicine. No specific negative events impacting its brand reputation in the past year were found in the search results.

Cryo-Cell International (CCEL) has a mix of institutional and individual owners. Major institutional shareholders include Hamilton Lane Advisors Llc, SFI Advisors, LLC, Vanguard Group Inc, Massmutual Trust Co Fsb, Partner Community, Inc, Geode Capital Management, LLC, Northern Trust Global Investments, Cerity Partners LLC, and BlackRock, Inc. Significant individual insider owners include Ki Yong Choi, David Portnoy, George Gaines, Brian L. Sheehy, Mark L. Portnoy, Mary J. Nyberg, and Andrew J. Filipowski.